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DNA methylation is one of many epigenetic marks, which directly modifies base 
residues, usually cytosines, in a multiple-step cycle. It has been linked to the regulation 
of gene expression and alternative splicing in several cell types, including during cell 
lineage specification and differentiation processes. DNA methylation changes have also 
been observed during aging, and aberrant methylation patterns have been reported in 
several neurological diseases. We here review the role of DNA methylation in Schwann 
cells and oligodendrocytes, the myelin-forming glia of the peripheral and central nervous 
systems, respectively. We first address how methylation and demethylation are regulating 
myelinating cells’ differentiation during development and repair. We then mention how 
DNA methylation dysregulation in diseases and cancers could explain their pathogenesis 
by directly influencing myelinating cells’ proliferation and differentiation capacities. 
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DNA methylation regulates Schwann cells and oligodendrocytes differentiation. 
DNA modifications are necessary for myelination or remyelinating events in the CNS. 
DNA methylation is dysregulated in myelinating glia in aging, in neurodegenerative 










Epigenetic regulation is composed of several layers of modifications, from 
regionally-restricted marks on DNA and histones, to more global remodeling of chromatin 
regions. DNA methylation is the first layer of these epigenetic processes, as it directly 
modifies base residues, on cytosines and to a lower extent on adenines. DNA 
modifications mainly target the cytosine residues at their C-5 position, essentially at CpG 
dinucleotides in mammalian genomes (Eden & Cedar, 1994; Lister et al., 2009). DNA 
methylation itself is a multi-step cycle, in which methylation is first initiated by the addition 
of a methyl group from S-adenosylmethionine on the C-5 position (5-methylcytosine, 
5mC), then demethylation is gradually induced by the oxidation of 5mC to 5-hydroxy-
methylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) 
(Hashimoto, Zhang, & Cheng, 2012; Huang & Rao, 2014; Lister et al., 2013; Meier & 
Recillas-Targa, 2017; H. Wu & Zhang, 2011) (Figure 1A). The first reaction is catalyzed 
by the DNA methyltransferases (DNMTs): the “maintenance” DNMT1, which is 
responsible for the faithful copying of DNA methylation from mother to daughter cells 
during replication, and the de novo DNMT3A and DNMT3B, which establish new 
methylation marks (Goll & Bestor, 2005; Lei et al., 1996; Lyko, 2018, p. 201; Okano, Xie, 
& Li, 1998). The demethylation reactions can be passive, but they are mainly catalyzed 
by the Ten-Eleven Translocations (TETs) enzymes, TET1, TET2 and TET3, which are 
differently expressed depending on the tissue type and also with age (Kriaucionis & 
Heintz, 2009; Rasmussen & Helin, 2016). The last demethylation step is catalyzed by 
thymine-DNA glycosylase (TDG), followed by base excision repair (BER) (Figure 1A).  
DNA methylation has been shown to have important roles in X-inactivation, 
genomic imprinting, transposon silencing, transcription factor binding, cellular 
differentiation, cancer and aging (Beerman et al., 2013; M. J. Jones, Goodman, & Kobor, 
2015; P. A. Jones, 2012; Yin et al., 2017). Generally, the level of methylation is higher in 
intergenic and repetitive regions of the genome and lower in gene regulatory areas, such 
as CpG islands (CGIs), transcription start sites, gene bodies and enhancer regions (P. A. 
Jones, 2012; Lister et al., 2009). At promoter regions and transcription starting sites, 5mC 
and 5hmC marks have mainly been associated with transcriptional repression and 
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initiation, respectively (Brenet et al., 2011; Schübeler, 2015; Smith & Meissner, 2013; 
Suzuki & Bird, 2008) (Figure 1B). Yet, while there is strong evidence for 5mC marks at 
CGIs at transcriptional start sites causing transcriptional repression, 5mC in other regions 
of the genome, particularly in enhancers and gene bodies, appears to be more dynamic 
and associated with both gene activation and repression (Deaton & Bird, 2011; P. A. 
Jones, 2012; Zhu, Wang, & Qian, 2016). Both 5mC and 5hmC marks could directly 
prevent the access of transcription factors to their binding sequence, especially for those 
containing a CG in their binding motif, or through binding partners such as methyl-CpG 
binding domain proteins. It is also worth noting that correlative assumptions between DNA 
methylation and gene expression have been recently challenged, as some studies have 
revealed modification of epigenetic marks following transcription. In these cases, DNA 
methylation and hydroxy-methylation marks would be revelators of ongoing or past gene 
expression and/or repression (Hodges et al., 2011; Lister et al., 2013; Stadler et al., 2011; 
Ziller et al., 2013). Specific DNA modifications could also recruit cofactors that modulate 
the chromatin environment, including histone modifications, which would imply a larger 
and more integrated role of several epigenetic marks in regulating gene expression (Jian 
Feng et al., 2015; Yiwei Liu, Zhang, Blumenthal, & Cheng, 2013; Schübeler, 2015; Smith 
& Meissner, 2013; Szulwach, Li, Li, Song, Han, et al., 2011; Yin et al., 2017). In gene 
bodies, 5mC and 5hmC marks have also been associated with alternative splicing 
(Gelfman, Cohen, Yearim, & Ast, 2013; Maunakea, Chepelev, Cui, & Zhao, 2013; Wan 
et al., 2013; Yearim et al., 2015). Less is known about the gene expression regulation by 
5fC and 5caC marks, but the recent development of new sequencing methods and 
specific antibodies for these marks will certainly lead to a better characterization of their 
respective biological roles. 
Methylation patterns remain reasonably static in terminally differentiated cells, 
whereas they are dynamically varied across cell types and developmental ages (J. Feng 
et al., 2010; Lister et al., 2013, 2009; Nestor et al., 2012, p. 201). During early cell lineage 
choice, in embryonic stem cells, binding sites of pluripotency-associated transcription 
factors have been shown to be enriched for DNA hydroxy-methylation (Ficz et al., 2011). 
In the nervous system, DNA methylation has been extensively studied in neurons and 
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astrocytes, which are both cell types that undergo several steps of lineage specification 
and cell differentiation (G. Fan et al., 2001; Guo et al., 2014; Hutnick et al., 2009; Kinde, 
Gabel, Gilbert, Griffith, & Greenberg, 2015; E. Li, Bestor, & Jaenisch, 1992; Milutinovic, 
Zhuang, Niveleau, & Szyf, 2003; Unterberger, Andrews, Weaver, & Szyf, 2006). During 
development, DNA methylation has been shown to be essential for determination of the 
neural lineage (Z. Wu et al., 2012), while demethylation has been reported to be 
associated with precocious astrogliogenesis, defective survival in proliferating 
neuroblasts and reduced neuronal plasticity in post-mitotic neurons (Guoping Fan et al., 
2005; J. Feng et al., 2010; Hutnick et al., 2009; Z. Wu et al., 2012). 
The myelinating cells of the peripheral nervous system (PNS) and the central 
nervous system (CNS), Schwann cells and oligodendrocytes, also undergo multiple cell 
lineage specification steps before terminally differentiating. A tight dynamic control of 
transcription factors is necessary for normal myelination, and their dysregulation, in 
cancers, diseases and aging, and has been directly linked to glial cell proliferation or 
differentiation defects. Here, we review the role of DNA methylation in the Schwann cell 
and oligodendroglial lineages, during the myelination process in development and in the 
adult, as well as in injury, cancer and aging. 
 
 
2. DNA methylation in Schwann Cells 
2.1. The Schwann cell lineage  
Schwann cells are amongst the major glial cell types of the mammalian PNS, 
alongside enteric glia from the gut and satellite glia from the dorsal root ganglia. Currently, 
there are four known types of Schwann cells, though this number will likely grow with 
future studies. Myelinating and Remak (non-myelinating) Schwann cells are found in 
spinal nerves and are associated with large and small caliber axons, respectively. 
Whereas terminal Schwann cells and nociceptive Schwann cells are associated with 
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nerve terminals of motor and nociceptive neurons, respectively (Abdo et al., 2019; Jessen 
& Mirsky, 2019). Schwann cells are generated from neural crest cells and pass through 
two well characterized developmental stages before differentiating into myelinating or 
Remak Schwann cells around birth. These stages are known as the Schwann cell 
precursor and the immature Schwann cell (Jessen & Mirsky, 2019).  
More recently an additional Schwann cell state was identified. After injury to the 
adult PNS, myelinating and Remak Schwann cells transform into repair Schwann cells to 
promote nervous system regeneration (Arthur-Farraj et al., 2012; Gomez-Sanchez et al., 
2017; Jessen & Arthur-Farraj, 2019). Repair Schwann cells can have subtly different 
molecular phenotypes depending on their vicinity to the site of injury (Clements et al., 
2017). Following axon regeneration, they can re-differentiate into either myelinating or 
Remak Schwann cells, independent of their original phenotype (Stierli et al., 2018). 
Importantly, repair Schwann cells appear to be lineage-restricted and incapable of 
transforming into other cell types or of forming tumors, without further mutation or 
manipulation of their genome (Parfejevs, Antunes, & Sommer, 2018; Stierli et al., 2018). 
 
2.2. DNA methylation regulates Schwann cell myelination 
Both DNMT3A and DNMT3B are important for neural crest specification and the 
timing of their differentiation (for review see (Hu, Strobl-Mazzulla, & Bronner, 2014)). In 
the absence of DNMT3A in the chick embryo there is a failure to repress neural genes, 
Sox 2 and Sox3 in the prospective neural crest region and a subsequent loss of neural 
crest specifier genes, Sox10, Foxd3 and Snail2 (Hu, Strobl-Mazzulla, Sauka-Spengler, & 
Bronner, 2012). Loss of DNMT3B in both human embryonic stem cells and in the chick 
embryo leads to acceleration of neural crest differentiation and precocious peripheral 
neuronal differentiation (Hu, Strobl-Mazzulla, Simoes-Costa, Sánchez-Vásquez, & 
Bronner, 2014; Martins-Taylor, Schroeder, LaSalle, Lalande, & Xu, 2012). In the chick, 
DNMT3B binds and methylates the Sox10 promoter, which represses Sox10 expression, 
allowing for cessation of neural crest delamination (Hu, Strobl-Mazzulla, Simoes-Costa, 
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et al., 2014). It is currently unknown whether DNA methylation regulates the generation 
or behavior of Schwann cell precursors or Immature Schwann cells. Immature Schwann 
cells begin to myelinate after they select an axon through a process known as radial 
sorting (Monk, Feltri, & Taveggia, 2015). Schwann cells receive signals to myelinate from 
their basal lamina, most prominently through interaction of laminin-221 with the G-protein 
coupled receptor, GPR126, signaling through a cyclic AMP/protein kinase A axis (Mogha 
et al., 2013; Monk et al., 2009; Petersen et al., 2015). Additionally, Schwann cells also 
receive signals from the axon that regulate myelination, the most studied of these is 
Neuregulin 1 type III binding to ErbB receptors (Michailov et al., 2004; Taveggia et al., 
2005). These signals coalesce on a number of transcription factors to regulate myelin 
gene expression, such as Egr2/Krox-20 and Yy1 ((Ye He et al., 2010), reviewed in 
(Herbert & Monk, 2017; Monk et al., 2015)). 
Myelination begins in mouse nerves at birth (Monk et al., 2015). A genome wide 
CpG methylation study using reduced representation bisulfite sequencing compared 
mouse newborn nerves to adult mature myelinated postnatal day 60 (P60) nerves. They 
showed that promoter and regulatory regions for a number of myelin genes, such as Mbp 
and Pmp22 became globally hypo-methylated by P60 and this broadly correlated with an 
up-regulation in myelin gene expression between these two time points. Moreover, 
binding sites for myelin-specific transcription factors, such as Egr2 and Yy1 were found 
to be enriched in the hypo-methylated regions (Varela-Rey et al., 2014) (Figure 2). It is 
important to note that the investigators found that, genome-wide, DNA hypo-methylation 
was associated with both up- and down-regulation of gene expression, which mirrors 
findings from other tissues (P. A. Jones, 2012). Although Varela-Rey et al. found that 
regulatory regions of a number of myelin genes became progressively more hypo-
methylated, the relationship of DNA methylation with global myelin gene expression 
appears more complex. This is because most myelin genes were progressively up-
regulated after birth (P10), while myelination proceeded, and then down-regulated again, 
albeit to levels higher than at newborn, in the adult nerve (P60) (Varela-Rey et al., 2014). 
Additionally, there are two further considerations to take into account with the 
interpretation of these findings. Firstly, Schwann cells are actively proliferating in the early 
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postnatal nerve and this could certainly contribute to some of the reduction in global CpG 
methylation observed in the adult nerve. Secondly, genome wide hypo-methylation is a 
phenomenon that is observed in many tissues with aging and it is possible that some of 
the hypo-methylation seen between newborn and P60 sciatic nerve could be related to 
the aging process (M. J. Jones et al., 2015). Despite this, genetically increasing the global 
level of DNA methylation in the mouse sciatic nerve through knockout of Gnmt, an 
enzyme that regulates the level of S-adenosylmethionine, the major methyl donor, led to 
thinner myelin sheaths and a reduction in expression of a number of lipid metabolism 
genes important in the myelination process (Varela-Rey et al., 2014) (Figure 2). This 
does demonstrate that altering methylation levels can regulate Schwann cell myelination 
in vivo, however it remains uncertain what the relative contribution of methylation of DNA 
versus histones contributes to this phenotype and whether it occurs through a Schwann 
cell autonomous mechanism.  
Cyclic AMP has been identified as a signal that could regulate the level of DNA 
methylation in Schwann cells during myelination. Firstly, treating cultured Schwann cells 
with cyclic AMP analogues, an in vitro assay for myelin differentiation, induces global CpG 
hypo-methylation of the Schwann cell methylome (Varela-Rey et al., 2014). Additionally, 
it has been shown that elevation of cyclic AMP levels in Schwann cells, in vitro, can 
increase 5hmC in promoters and gene bodies of up-regulated myelin genes (e.g. Prx and 
Mbp), likely through increasing the bioavailability of TETs cofactor Fe2+, in a process that 
is independent of protein kinase A activation (Camarena et al., 2017) (Figure 2). In 
support of this, the activity of TETs in the sciatic nerve significantly increases as 
myelination proceeds (Varela-Rey et al., 2014). Genome-wide profiling of 5hmC has yet 
to be performed in peripheral nerve but in the CNS, it has been shown that hydroxy-
methylation is a relatively abundant epigenetic mark compared to other tissues and is 
enriched in enhancers and gene bodies while largely absent from transcriptional start 
sites (Szulwach, Li, Li, Song, Wu, et al., 2011).  
While these studies implicate CpG methylation and potentially hydroxy-
methylation in regulating myelination in the PNS, we still do not know the relative roles of 
the DNMTs and TETs enzymes in the Schwann cell lineage. Furthermore, it is likely that 
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global DNA hypo-methylation is not the principal molecular mechanism driving 
myelination but works in concert with histone modifications, transcription factor binding 
and microRNA mediated post-transcriptional processing, which all have substantial roles 
in initiating myelination (reviewed in this issue by N. Tapinos and C. Jacob, and by M. 
Wegner). Finally, single-cell methylome studies will be required to further clarify the 
methylome signature in the Schwann cell lineage and, in particular, how the methylome 
of Remak Schwann cells differs from that of myelinating Schwann cells in adult peripheral 
nerves. 
 
2.3. Schwann cell methylome changes after nerve injury 
Whole genome shotgun bisulfite sequencing of sciatic nerve seven days after 
nerve transection demonstrated relatively few methylation changes (853 differentially 
methylated CpGs out of over 4 million identified) compared to uninjured nerves (Arthur-
Farraj et al., 2017). At this time point post-nerve injury, all Schwann cells are either in the 
process of or are already transformed into repair Schwann cells (Arthur-Farraj et al., 2012; 
Gomez-Sanchez et al., 2017). One caveat to this kind of analysis is that Schwann cells 
compose 80% of the uninjured and between 50-70% of the injured peripheral nerve, 
raising the possibility that other cell types could contribute to the methylation signatures. 
While this cannot be completely excluded without performing single cell methylation 
analysis, the in vivo methylation profile of the injured nerve was strongly correlated with 
the methylation profile of cultured Schwann cells (which have similar morphology and 
gene expression to repair Schwann cells) but not macrophages, cultured endoneurial 
fibroblasts or perineurial cells (Arthur-Farraj et al., 2017). Often, global methylation 
changes are the hallmark of loss of lineage restriction and tumorigenesis (Baylin & Jones, 
2016). The fact that we detected relatively few methylation changes after injury might 
reflect the observation that myelinating and Remak Schwann cells remain lineage 
restricted after conversion to repair Schwann cells and are not multipotent (Stierli et al., 
2018).  
 11 
Schwann cells react to injury by down-regulating myelin genes and up-regulating 
developmental genes, alongside expression of a new program of genes specialized for 
repair (Jessen & Arthur-Farraj, 2019). Furthermore, repair Schwann cell morphology is 
radically different to that of immature Schwann cells (Gomez-Sanchez et al., 2017). In 
line with this, the DNA methylation changes occurring during myelination in development 
are not reversed upon injury, as one might expect if this was simply de-differentiation 
(Arthur-Farraj et al., 2017; Varela-Rey et al., 2014). Together, this shows that the 
Schwann cell reaction to injury cannot be classified solely as ‘de-differentiation’, which it 
is often referred to as, but instead as an adaptive change of cellular state, which is 
required to promote effective nerve repair (Jessen & Arthur-Farraj, 2019; Jessen, Mirsky, 
& Arthur-Farraj, 2015) (Figure 2). 
 Among the limited methylation changes observed in the injured nerve, the majority 
of differentially methylated regions (DMRs) were localized in regulatory regions of the 
genome, including putative enhancer regions. DMRs in these regions showed enrichment 
of genes associated with ErbB, TGFb and neurotrophin signaling, and occurred in the 
vicinity of binding sites for AP1 family, BACH2, MAFK and BATF transcription factors 
(Arthur-Farraj et al., 2017). Working in concert with other epigenetic modifications during 
nerve injury, DNA methylation changes may regulate expression of certain sets of genes 
through differential enhancer methylation and subsequent alteration of transcription factor 
binding. Conversely, altered methylation may occur as a result of transcription factor 
binding (Schübeler, 2015). The DNA demethylase, TET2 has been identified as having 
an important role in regulating enhancer methylation (Lister et al., 2013). In light of this, it 
would be particularly interesting to investigate whether TET2 and have a role in regulating 
demethylation/hydroxy-methylation at enhancers in Schwann cells.  
 
 
3. DNA methylation in oligodendrocytes 
3.1. The oligodendroglial cell lineage 
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 Oligodendrocytes (OLs), the myelinating cells of the CNS, emerge from 
oligodendrocyte progenitor cells (OPCs), themselves deriving from neural stem cells. The 
switch from highly proliferative and migrative cells, characteristic of OPCs, to 
differentiating and ensheathing cells, specific to OLs, is regulated by the dynamic and 
orchestrated expression of specific transcription factors, from early specification (e.g. 
Ascl1, Olig1/Olig2, Sox10) to late maturation (e.g. Yy1, Myrf, Zfp191) (Emery et al., 2009; 
Y. He et al., 2007; Howng et al., 2010; Küspert & Wegner, 2016; Q. R. Lu et al., 2002; 
Nakatani et al., 2013). These processes are also regulated by epigenetic modifications, 
including chromatin remodeling (reviewed in this issue by C. Parras and QR. Lu), histones 
modifications (reviewed in this issue by J. Liu and G. Castelo-Branco) and DNA 
methylation. 
 
3.2. DNA methylation in oligodendroglial cells during developmental myelination 
DNA modification enzymes, DNMTs and TETs, are highly enriched in brain, liver 
and reproductive tissues, which correlate with high DNA methylation and hydroxy-
methylation levels in the CNS, compared to other tissues (Globisch et al., 2010; W. Li & 
Liu, 2011; Ono, Uehara, Kurishita, Tawa, & Sakurai, 1993; Szulwach, Li, Li, Song, Wu, et 
al., 2011; Tawa, Ono, Kurishita, Okada, & Hirose, 1990). However, their levels at specific 
genomic regions dynamically vary during oligodendroglial cell development, from their 
specification to their differentiation. 
In early developmental stages, specification of cortical neural stem cells into the 
glial lineage has been shown to be regulated by two successive DNA methylation waves,  
first global demethylation, followed by specific methylation and silencing of neuronal 
genes (Guo et al., 2014; Oswald et al., 2000; Sanosaka et al., 2017; Z. Wu et al., 2012). 
Low-methylated regions at promoters of astrocyte- and oligodendrocyte-specific genes 
are also enriched for gliogenic transcription factors, such as the nuclear factor I-binding 
motif, which are necessary to drive glial specification (Guoping Fan et al., 2005; Namihira 
et al., 2009; Sanosaka et al., 2017; Shu, Butz, Plachez, Gronostajski, & Richards, 2003). 
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Finally, acquisition of de novo methylation and hydroxy-methylation at specific astroglial 
(e.g. Gfap, genes involved in the JAK-STAT pathway) and oligodendroglial (e.g. Olig1, 
Sox10, Id2/4) genes distinguishes between these two glial lineages (Guoping Fan et al., 
2005; Hatada et al., 2008; Takizawa et al., 2001; Teter et al., 1996; H. Wu et al., 2010; 
M. Zhang et al., 2019) (Figure 3). 
The dynamic levels of DNA methylation and hydroxy-methylation in the 
oligodendroglial lineage, as well as their respective catalytic enzymes, DNMTs and TETs, 
suggest that these epigenetic marks are also essential for oligodendrocyte differentiation 
(Moyon et al., 2016; Y. Zhang et al., 2014; Zhao et al., 2014). An initial descriptive study 
detected a specific demethylation of the myelin gene, Mag, during OPC differentiation 
(Grubinska, Laszkiewicz, Royland, Wiggins, & Konat, 1994). Indeed, TET1, TET2 and 
TET3 have been shown to be necessary for OPC differentiation in vitro (Zhao et al., 2014). 
On the contrary, the blockade of the DNA methylation enzymes, in vivo, during rat CNS 
development, has been shown to delay myelination (Ransom, Yamate, Black, & Waxman, 
1985). However, this study was using a non-specific demethylating drug, which also 
affected RNA metabolism and post-transcriptional processes. More detailed whole-
genome methylome analysis comparing sorted neonatal OPCs and OLs has shown that 
OPC differentiation is associated with the same extent of hypo- as hyper-methylation. 
DNA methylation marks, identified by bisulfite-conversion sequencing, are mainly 
inversely correlated with gene expression during developmental myelination: genes with 
hypermethylated promoters and decreased expression in OLs compared to OPCs are 
associated with “neuronal lineage”, “cell cycle regulation” and “proliferation”, while genes 
with hypomethylated promoters and increased expression in OLs compared to OPCs are 
associated with “lipid processes” and “myelin components”. Decreasing methylation of 
differentiation genes after genetic ablation of Dnmt1 in OPCs was not sufficient to induce 
their differentiation, as it was also associated with reduced methylation and hence 
defective repression, of cell cycle genes and activation of genotoxic stress and the ER 
stress response. Conversely, RNA-Sequencing of in vitro OPCs lacking Tet1 revealed 
that downregulated genes were enriched for differentiation and cell cycle regulation 
genes. However, loss of Tet1 in neonatal OPC was not sufficient to block their proliferation 
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and differentiation in vitro and in vivo (Moyon et al., 2019; M. Zhang et al., 2019). This 
highlights a more complex role for DNA methylation in the oligodendroglial lineage, 
requiring both methylation and demethylation of specific genomic regions (Figure 3). 
Further analysis of the RNA-Sequencing of sorted control and Dnmt1-mutant OPCs also 
identified different alternative splicing events, correlated with massive hypo-methylation 
at the exon-intron boundaries (Moyon et al., 2016). On one hand, alternative splicing 
events have been shown to be necessary for oligodendrocyte differentiation during 
normal myelination (de Ferra et al., 1985; Jordan et al., 1990; Kevelam et al., 2015; Nave, 
Lai, Bloom, & Milner, 1987; Y. Zhang et al., 2014), and on the other hand, to be correlated 
with DNA methylation marks (Gelfman et al., 2013; Lev Maor, Yearim, & Ast, 2015; Wan 
et al., 2013; Yearim et al., 2015). In OPCs, the gene ontology of the alternative spliced 
transcripts is enriched for genes involved in the cell cycle process and myelination (Moyon 
et al., 2016). This shows that DNA methylation and demethylation directly affect gene 
expression and alternative splicing in OPCs, and are both required for normal myelination. 
Functional studies suggest specific roles for each DNMTs and TETs in the 
oligodendroglial lineage during development. Recently, in vitro loss-of-function 
experiments have shown that DNMT3A may participate in OPC survival and proliferation, 
while DNMT1 might be necessary for OPC differentiation (Egawa et al., 2019). DNMT1 
could also affect oligodendroglial cells survival in vitro, as it has already been observed 
in embryonic stem cell, but these results were not duplicated in vivo (Egawa et al., 2019; 
Liao et al., 2015). Indeed, the genetic ablation of Dnmt1 only – and not Dnmt3a – in vivo 
in OPCs (using Olig1-cre line) resulted in a severe hypo-myelination of the CNS, 
associated with tremors and decreased survival. In OPCs lacking Dnmt1, neither cell 
lineage specification nor survival were affected but, despite the hypomethylation of myelin 
genes, OPCs did not precociously proliferate or differentiate. Genetic ablation of Dnmt1 
or Dnmt3a, in vivo, in later stages of OL development (using Cnp-cre line) did not show 
any phenotype, which suggested that DNA methylation might only be required in the early 
steps of OPC differentiation in vivo (Moyon et al., 2016). This discrepancy suggests that 
in vitro and in vivo DNA methylation mechanisms might be slightly different, since 
epigenetic modifications can reflect extra-cellular and environmental cues. To better 
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correlate and understand the role of DNA methylation on gene expression and alternative 
splicing, it would also be necessary to analyze the different DNA methylation marks at the 
single-cell level in these knock-out mouse lines. Concerning DNA hydroxy-methylation, 
loss of Tet2 or Tet3 in the oligodendroglial lineage during developmental myelination did 
not show any phenotypes (Moyon et al., 2019; M. Zhang et al., 2019). While in vivo 
ablation of Tet1 in OPCs (using Olig1-cre line) appears to result in a lower number of 
embryonic OPCs and slightly delayed OL differentiation at early stages (post-natal day 
14), only in brain regions, the extent of the myelination and its ultra-structure in adult 
animals are comparable to controls (post-natal day 60) (M. Zhang et al., 2019). This would 
suggest that DNA hydroxy-methylation and its respective enzymes are not required for 
neonatal OPC differentiation during developmental myelination. 
 
 
3.3. DNA methylation in oligodendroglial cells, in adult and aging 
During development, a pool of undifferentiated adult OPCs is maintained and 
uniformly distributed in the grey and white matter of the adult CNS (Chang, Nishiyama, 
Peterson, Prineas, & Trapp, 2000; Dawson, Polito, Levine, & Reynolds, 2003; Pringle, 
Mudhar, Collarini, & Richardson, 1992; Wolswijk & Noble, 1989). Adult OPCs are not only 
immature and on-standby cells, as once thought. More and more evidence has confirmed 
their essential roles in the adult CNS, which includes directly regulating neuronal, glial 
and vascular systems (Frühbeis et al., 2013; Gautier et al., 2015; Hayakawa et al., 2011; 
Pham et al., 2012). They are also the main myelinating cells of the adult CNS, necessary 
for myelin remodelling, plasticity, learning and for remyelination (Bengtsson et al., 2005; 
Fancy et al., 2011; I. A. McKenzie et al., 2014; Young et al., 2013). However, adult OPCs 
have different proliferation, migration and differentiation capacities than neonatal OPCs, 
which result from their different transcriptomic profiles (Chari, Crang, & Blakemore, 2003; 
Clarke et al., 2012; Lin, Mela, Guilfoyle, & Goldman, 2009; Marques et al., 2016; Moyon 
et al., 2015; Spitzer et al., 2019). Many epigenetic marks have been demonstrated to 
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change with aging, but DNA methylation, especially, has been identified as the prominent 
epigenetic clock or age predictor (Bell et al., 2012; Hernandez et al., 2011; Horvath, 2013; 
Horvath & Raj, 2018; Masser et al., 2018; Shen et al., 2008; Stubbs et al., 2017; 
Szulwach, Li, Li, Song, Wu, et al., 2011; Unnikrishnan et al., 2019). This suggests that 
phenotypic differences observed between adult OPCs and neonatal OPCs could also 
reflect age-related methylomic changes. 
The role of DNA methylation and DNMTs has recently been reported in vivo in adult 
OPCs during remyelination. Genetic ablation of Dnmt1 and/or Dnmt3a in the 
oligodendroglial lineage impairs OPC differentiation into mature OLs, leading to thinner 
and delayed remyelination, following lysolecithin-induced focal demyelination in ventral 
spinal cords (Moyon et al., 2017). Interestingly, loss of a single Dnmt is less dramatic than 
loss of both Dnmt1 and Dnmt3a, suggesting compensatory or redundant roles for DNMTs 
in adult OPCs, an observation not seen in neonatal OPCs. The lack of Dnmt1 reduced 
differentiation in both neonatal and adult OPCs, but only proliferation in neonatal OPCs 
(Moyon et al., 2016, 2017) (Figure 3). This suggests an age-dependent role for DNA 
methylation in OPC differentiation. One caveat with this conclusion is that the neonatal 
and adult studies used slightly different genetic strategies (i.e. Olig1-cre line targeting 
early progenitors in developmental brain and Plp-cre line targeting newly formed 
oligodendrocytes in adult brain), so the effects observed on the cell cycle may simply 
reflect the distinct proliferative potential of these two targeted cell populations, and not 
only their age-related differences (Moyon et al., 2016, 2017). Future parallel studies 
comparing the contribution of DNA methylation to neonatal and adult progenitor function 
are needed to fully address these issues. 
In adult human tissues, TET genes have been shown to be enriched in the 
oligodendroglial lineage compared to neuronal subtypes. DNA methylation and hydroxy-
methylation levels appear to be cell type-specific in the adult CNS, which might suggest 
an interesting specification role in each cell lineage, including oligodendrocytes 
(Kozlenkov et al., 2018). Recent studies have functionally shown that TET1 – and not 
TET2 or TET3 – is the main DNA hydroxy-methylation enzyme regulating adult OPC 
differentiation (Moyon et al., 2019; M. Zhang et al., 2019). Following lysolecithin-induced 
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lesion in young adult ventral spinal cords, efficient remyelination appears to be correlated 
with high TET1 expression and increased DNA hydroxy-methylation in the 
oligodendroglial population. Moreover, ablation of Tet1 in the oligodendroglial lineages 
impaired OL differentiation and delayed remyelination. In aging mice, defective 
remyelination was also associated with lower TET1 expression and no increased DNA 
hydroxy-methylation in the oligodendroglial cells. Interestingly, impaired remyelination 
observed in young mice lacking Tet1 seems to recapitulate the hallmarks of an aging 
phenotype, such as delayed repair and ultra-structural peri-axonal swellings, which would 
eventually lead to defective neuronal functions (Moyon et al., 2019). Altogether, these 
new evidences highlight the essential role of TET1-mediated DNA hydroxy-methylation 
in adult OPC, especially after injury, and its potentially deleterious role during aging repair. 
 
 
3.4. DNA methylation in oligodendroglial cells in diseases 
Epigenetic mechanisms, including DNA methylation, have particular relevance for 
human neurodegenerative and psychiatric disease. The development of genome-wide 
DNA methylation studies of human post-mortem brain tissues has highlighted methylation 
and demethylation changes in Alzheimer’s disease, Parkinson disease, amyotrophic 
lateral sclerosis and schizophrenia (Chestnut et al., 2011; Desplats et al., 2011; Jaffe et 
al., 2015; P. Li et al., 2019; Semick et al., 2019). These datasets have mainly been 
performed on whole-tissue, and their analysis have followed an historically neuro-centric 
hypothesis. Though previously overlooked, the role of oligodendroglial cells in 
neurological disorders has recently been the focus of a number of studies (Chen, Huang, 
Michael, & Xiao, 2015; A. T. McKenzie et al., 2017; Nasrabady, Rizvi, Goldman, & 
Brickman, 2018; Nguyen et al., 2013). New single-nucleus isolation and sequencing 
technology have now noted specific DNA methylation changes in oligodendroglial 
populations in Alzheimer’s disease and in schizophrenia. In these studies, DNA 
methylation changes appeared to be as frequently represented in the oligodendroglial 
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population as in the neuronal population, but occurring at different genomic regions 
between the two cell populations (Gasparoni et al., 2018; Mendizabal et al., 2019). DNA 
methylation dysregulation in OPCs and OLs could be associated with several pathologies, 
as patients with deficiency in S-adenosylhomocysteine hydrolase have been observed to 
also present correlative CNS hypomyelination (Barić et al., 2004). 
Indeed, alterations in DNA methylation have been reported in diseases that affect 
the oligodendroglial lineage, such as Multiple Sclerosis (MS). MS is a common immune-
mediated CNS disease, characterized by oligodendroglial loss and focal attacks of 
demyelination, which are frequently associated with neurodegeneration (Ghosh et al., 
2011; International Multiple Sclerosis Genetics Consortium*†, 2019; Oluich et al., 2012). 
A recent study has shown that DNMTs are up-regulated and TETs down-regulated in 
demyelinated areas of the hippocampus from MS patients, which would suggest that one 
would expect an increase in methylation in MS tissues (Chomyk et al., 2017). However, 
DNA methylation sequencing of MS-affected brain tissues revealed a variety of 
methylomic changes in MS-affected normal appearing white matter (NAWM) and 
hippocampus compared to controls. For example, genes known to regulate 
oligodendroglial survival and differentiation (i.e. BCL2L2, NDRG1, NFASC) are hyper-
methylated and down-regulated in MS NAWM samples, which could affect the OPCs’ 
response capacities and overall remyelination in patients (Chomyk et al., 2017; Huynh et 
al., 2014). In contrast, genes implicated in proteolytic processing (i.e. LGMN, CTSZ, 
PAD2) are hypo-methylated and up-regulated in MS NAWM samples, which could even 
have the capacity to trigger the disease (Chomyk et al., 2017; Huynh et al., 2014; 
Mastronardi, Noor, Wood, Paton, & Moscarello, 2007). Indeed, PAD2 can citrullinate 
myelin basic protein (MBP), which results in the breakdown of myelin, the release of 
myelin protein fragments and a subsequent immune response (Mastronardi & Moscarello, 
2005; Mastronardi et al., 2006). Citrullination of MBP has been shown to be elevated in 
MS tissues compared to controls, which directly correlates with hypo-methylation and up-
regulation of PAD2, and with increased levels of PAD2 enzyme (Mastronardi et al., 2007; 
Moscarello, Wood, Ackerley, & Boulias, 1994). These findings suggest that complex DNA 
methylation changes in OPCs and OLs could contribute to MS pathology, possibly by 
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affecting both demyelination and remyelination. Knowing the predominant incidence of 
MS in women compared to men, it is also worth noting that a recent study has shown that 
DNA methylation changes observed during aging in mouse hippocampus were sex-
specific. DNA methylation did not differ between males and females in young tissues but 
more than 95% of age-related changes occurred in methylation at specific sites in one 
sex but not the other (Masser et al., 2017). Further oligodendroglial-specific and sex-
specific analysis would be interesting to address the potential role of DNA methylation in 





4. The role of DNA methylation in Schwann cell and oligodendroglial tumors  
4.1. Glial origin of some PNS and CNS tumors 
The main Schwann cell tumors are benign Schwannomas and neurofibromas, and 
malignant peripheral nerve sheath tumors (MPNST) (for reviews see (Evans et al., 2002; 
Hilton & Hanemann, 2014; Ratner & Miller, 2015)). The commonest genetic abnormality 
found in sporadic Schwannomas is mutation in the NF2 gene, which codes for the protein, 
Merlin (Hilton & Hanemann, 2014). Patients with neurofibromatosis type 1 (NF1), develop 
amongst other neoplasms, cutaneous and plexiform neurofibromas, which are thought to 
be predominantly Schwann cell tumors but which also contain other cell types. All 
neurofibromas are associated with bi-allelic inactivation of the NF1 gene, which codes for 
the tumor suppressor protein, neurofibromin, an inhibitor of RAS signaling (Ratner & 
Miller, 2015). In a proportion of NF1 patients, plexiform neurofibromas will transform into 
MPNSTs, however 50% of MPNST do occur sporadically. These tumors are highly 
aggressive and generally have a poor prognosis (Farid et al., 2014). 
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Gliomas are the most common type of primary brain tumors in adults and they are 
usually characterized by poor prognoses (Ohgaki & Kleihues, 2005). Molecular 
characterization of gliomas suggest that they originate from proliferative cells, such as 
neural stem cells, astrocytes and OPCs (for review see (Zong, Parada, & Baker, 2015)). 
Histopathological analysis of human glioma samples (e.g. expression of OPC-specific 
markers, such as NG2 and Olig2) and analysis of the molecular signature of proneural 
glioblastomas (e.g. expression of PDGFRa, NKX2-2, OLIG2) strongly suggest an 
oligodendroglial origin (Ligon et al., 2004; Q. Richard Lu et al., 2001; Shoshan et al., 
1999; Verhaak et al., 2010). Proneural gliomas present alterations of PDGFRa, such as 
mutations and/or amplifications, often associated with point mutations in tumor protein 
gene TP53 and in isocitrate dehydrogenase (IDH) 1 (Verhaak et al., 2010). Interestingly, 
three recent studies even highlighted the synaptic interaction of OPC-like cells with neural 
circuits in gliomas, which might promote their progression (Venkataramani et al., 2019; 
Venkatesh et al., 2019; Zeng et al., 2019).  
4.2. Aberrant DNA modifications in Schwannomas and glioblastomas 
Aberrant DNA methylation is strongly implicated in tumorigenesis. There are three 
ways DNA methylation can contribute to an oncogenic phenotype: firstly by enabling 
somatic and germline mutation through deamination of 5mC to thymine within gene 
bodies, following exposure to UV irradiation or carcinogens; secondly by global hypo-
methylation; and thirdly by hyper-methylation of CGI promoters of tumor suppressor 
genes (Baylin & Jones, 2016). 
In some gliomas, OPC proliferation and apoptosis dysregulation has been directly 
linked to mutation of genes involved in the DNA methylation/demethylation cycle. IDH1/2 
mutation, which is frequently detected in these types of cancers, has been shown to 
induce the accumulation of 2-Hydroxyglutarate, inhibiting Alpha-Ketoglutarate-dependent 
deoxygenase and the metabolic-epigenetic interplay, leading to alteration of both histone 
and DNA methylation patterns (Christensen et al., 2011; Ohba & Hirose, 2018; Unruh et 
al., 2019; Yan et al., 2009). 
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Many tumors, and especially gliomas, have been characterized by extensive global 
DNA hypo-methylation, associated with aberrant activation of genes and non-coding 
regions (Chou et al., 2012; Chu et al., 2011; Felsberg et al., 2006; Jia et al., 2019; 
Sharma, Kelly, & Jones, 2010; Uhlmann et al., 2003; Watanabe & Maekawa, 2010; J. 
Zhang et al., 2016). Inversely, 5hmC enrichment, potentially allowing gene expression 
activation, has also been detected in enhancers implicated in glioma pathogenesis 
(Glowacka et al., 2018; Johnson et al., 2016). A number of studies have also shown that 
the significant DNA methylation changes observed in Schwann cell tumors are likely to 
contribute to their pathogenesis, as well as aid in their classification. Firstly, the global 
methylation profiles of Schwannomas differ based on their anatomical location, as cranial 
Schwannomas show different methylation patterns to spinal Schwannomas (Agnihotri et 
al., 2016). Genome-wide methylation mapping using MeDIP-Seq, which 
immunoprecipitates methylated DNA prior to whole genome sequencing, compared the 
methylome of benign Schwannomas, MPNSTs and cultured human Schwann cells. This 
study found over 100,000 DMRs between samples, including hyper-methylation of tumor 
suppressor genes, hypo-methylation of oncogenes and differential methylation of CGI 
shores. Yet, the most common methylation change was hypo-methylation of non-intronic 
satellite regions, particularly SATR1 and ARLalpha satellite repeat regions (Feber et al., 
2011). Microsatellite instability does not appear to be a frequent aberration in MPNSTs 
suggesting that hypo-methylation of these regions may have a more complex role, 
possibly in the regulation of nearby genes, though this remains to be tested (Serra et al., 
1997). A genome-wide methylation microarray of vestibular Schwannomas demonstrated 
a trend towards hypo-methylation with more differential methylation identified away from 
CGIs, similar to the findings in MPNSTs (Feber et al., 2011). Significant hypo-methylation 
of the Hox gene cluster was identified as a commonly occurring alteration but this study 
did not identify any NF2 promoter hypermethylation, unlike previously (Feber et al., 2011; 
Gonzalez-Gomez, Bello, Arjona, et al., 2003; Torres-Martín et al., 2015).  
In parallel, tumors, such as gliomas, have been characterized by regional DNA 
hyper-methylation at specific loci, correlated with silencing of tumor suppressor genes 
(Chou et al., 2012; Chu et al., 2011; Felsberg et al., 2006; Jia et al., 2019; Sharma et al., 
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2010; Uhlmann et al., 2003; Watanabe & Maekawa, 2010; J. Zhang et al., 2016). In 
Schwannomas and MPNSTs, a number of early and targeted studies have also identified 
promoter hyper-methylation of tumor suppressor genes and their subsequent inactivation, 
which appeared as potential mechanism for how aberrant DNA methylation contributes 
to tumorigenesis (Gonzalez-Gomez, Bello, Alonso, et al., 2003; Gonzalez-Gomez, Bello, 
Arjona, et al., 2003; Kawaguchi et al., 2006; Kino et al., 2001; Oh et al., 2015). Promoter 
hyper-methylation of the downstream effectors of Merlin/NF2, Lats1 or Lats2, has been 
described in Schwannomas and it was recently shown in mice that specific deletion of 
both Lats1 and Lats2 in Schwann cells can lead to MPNST generation (Oh et al., 2015; 
L. M. N. Wu et al., 2018). In contrast to Nf2, hyper-methylation of the Nf1 promoter does 
not seem to occur in Schwann cell tumors (Feber et al., 2011; Fishbein, Eady, Sanek, 
Muir, & Wallace, 2005; Harder et al., 2004; Luijten et al., 2000). However, site specific 
methylation of discrete CpGs in SP1, AP2 and CRE binding sites in the Nf1 promoter may 
affect transcription factor binding and NF1 expression in neurofibromas and MPNSTs 
(Harder et al., 2004; Kino et al., 2001; Mancini, Singh, Archer, & Rodenhiser, 1999).  
DNA methylation modifications have been highly correlated with tumorigenesis 
and prognosis of Schwannomas, MPNSTs, and gliomas, which suggests that specific 
methylating and demethylating agents could be potential therapies to prevent cancer cell 
progression in these tumours (Aoki & Natsume, 2019; de Souza et al., 2018; Heiland et 
al., 2016; Yanwei Liu et al., 2015; Ohba & Hirose, 2018). Certainly epigenetic therapies 
targeting the polycomb repressive complex 2 (PRC2) are a promising current avenue of 
research for MPNSTs and high grade gliomas given genetic studies strongly implicate 
PRC2 and loss of Histone H3K27 methylation in their progressions (De Raedt et al., 2014; 
Filbin et al., 2018; Lee et al., 2014; Nagaraja et al., 2017; Natalie Wu & Lu, 2019; M. 
Zhang et al., 2014). Presently, the main challenges facing the field are to discern whether 
the differential methylation observed in tumors are more cause or consequence of the 
oncogenic process. Furthermore, what role does the DNA methylation machinery have in 
the development of Schwannomas, MPNSTs and gliomas? Finally, we still don’t 
understand the hierarchical interaction between DNA methylation, histone modifications 
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and chromatin states within individual tumor cells and this needs to be addressed to 
develop better future treatments (Baylin & Jones, 2016). 
 
 
4. Concluding remarks  
A growing body of evidence supports a prominent role for both DNA methylation 
and potentially DNA hydroxy-methylation in Schwann cells and oligodendroglial cells 
lineages, during development and in a number of neurological diseases, including tumors. 
A better integration of these specific 5mC and 5hmC marks with other epigenetic layers, 
such as histone modifications, chromatin remodeling or microRNA post-transcriptional 
processing, would be essential to clearly map their respective roles on gene regulation 
during myelinating cells proliferation and differentiation processes. New tools, including 
specific 5fC and 5caC antibodies and sequencing techniques, should also now allow a 
better comprehension of these DNA modifications marks. Single-cell sequencing coupled 
with methylome analysis would be essential to precisely address the functional role of 
epigenetic marks, which are highly specific between each cell type and within each 









Figure 1. DNA methylation/demethylation cycle 
(A) A class of enzymes called DNA methyltransferases (DNMT1, DNMT3A, 3B) methylate 
cytosines (C) by transferring a methyl group from S-adenosylmethionine (SAMe). 5-
methylcytosine (5mC) can be oxidized by ten eleven translocation (TET) enzymes (TET1, 
TET2, TET3) to 5-hydroxy-methylcytosine (5hmC), to 5-formylcytosine (5fC), then 5-
carboxylcytosine (5caC). The last demethylation step is catalyzed by thymine-DNA 
glycosylase (TDG), followed by base excision repair (BER). (B) Generally, DNA 
methylation (5mC) marks are associated with gene repression, while DNA hydroxy-








Figure 2. DNA methylation in Schwann cells during myelination and after nerve 
injury. 
The transition from immature Schwann cell to myelinating Schwann cell is accompanied 
by hypomethylation of promoters and enhancers of myelin and lipid biosynthetic pathway 
genes. The DNA methyltransferase, Glycine N-methyltransferase (GNMT), which 
metabolizes S-Adenosylmethionine (SAMe), positively regulates the myelination process, 
whereas increases in the levels of SAMe negatively regulate myelination (Varela-Rey et 
al., 2014). The transformation of myelinating Schwann cells to Repair Schwann cells after 
nerve injury is accompanied by down-regulation of myelin genes, up-regulation of 
developmental genes and also of repair program genes (Jessen & Arthur-Farraj, 2019). 
There are no global methylome changes in Schwann cells upon nerve injury but discrete 








Figure 3. DNA methylation in oligodendroglial cell differentiation during 
myelination and remyelination. 
Oligodendroglial cell lineage differentiation is regulated by both DNA methylation and 
demethylation. Early DNA methylation of neuronal and astroglial lineage genes induce 
oligodendroglial specification. During oligodendrocyte progenitor cell differentiation, DNA 
methylation – mediated by DNMT1 during development and mainly DNMT3A in adult - 
has been associated with transcriptional repression of proliferation genes and of inhibitor 
of differentiation genes. In contrary, DNA demethylation has been observed on 
differentiation and myelin genes, resulting from TET activity that induces the OPC 
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